KRAS mutations are among the most common oncogenic alterations in human cancers. Historically, KRAS has been considered "undruggable" due to its high affinity for GTP/GDP and the absence of suitable binding pockets. However, recent breakthroughs have led to the development of direct KRAS inhibitors.
